ForwardHealth Pharmacy Data Table

Diagnosis Restrictions

Note: Prescribers are required to indicate the diagnosis code or description on prescriptions for diagnosis-restricted drugs. If a diagnosis code is not indicated on the prescription, pharmacy providers should contact the prescriber to obtain the diagnosis code or description. *It is not acceptable for pharmacy providers to obtain the diagnosis code or description from the member.*

All diagnosis codes indicated on claims (and PA requests when applicable).

Preferred Diagnosis-Restricted Drugs

Pharmacy providers should submit the most specific ICD-9-CM diagnosis code on claims for preferred drugs.

Non-preferred Diagnosis-Restricted Drugs

Prescribers should indicate the most specific ICD-9-CM diagnosis code for non-preferred drugs on the Prior Authorization/Preferred Drug List (PA/PDL) Exemption Request.

Diagnosis Outside the Allowed Diagnoses

BadgerCare Plus Standard Plan, Medicaid, and Senior Care

If the prescriber writes a prescription with a diagnosis outside the ForwardHealth-allowed diagnoses for a drug, the prescriber is required to submit peer-reviewed medical literature to support the proven efficacy and safety of the requested use of the drug. Documentation of previous treatments and detailed reasons why other covered drug treatments were discontinued or not utilized are required. Medical records should be provided as necessary to support the PA request. This information should be documented on the PA/DGA in Section V (Clinical Information for Diagnosis-Restricted Drug Requests).

When completing the PA/DGA, prescribers should provide the diagnosis code and description, complete Section V, and use Section VIII (Additional Information), if needed. Prescribers are reminded to provide a handwritten signature and date on the form before submitting it to the pharmacy provider where the prescription will be filled. The pharmacy provider is required to complete a PA/RF before submitting the forms and supporting documentation to ForwardHealth. Prescribers should not submit PA forms to ForwardHealth.

As a reminder, prescribers and pharmcy providers are required to retain a completed copy of the PA form(s).

| | | | | October 1, 201 |
|-----------------------|---|--------------------------------|------------------|--|
| Therapeutic Class | Generic Name | Brand Name | Diagnosis Ranges | Description |
| Analgesics, Narcotics | | | | |
| Agonist-Antagonist. | | | | |
| <u>(Requires PA)</u> | Buprenorphine Buprenorphine/Naloxone | Subutex Suboxone Zubsolv | 30400> 30403 | Opioid Type Dependence |
| (Non-Covered Service | | | | |
| for codes not listed) | | | | |
| Anticoagulants | Apixaban | Eliquis | 42731 | Atrial Fibrillation |
| Antidiarrheal | Crofelemer | Fulyzaq | 042 | HIV Disease |
| | | | 07953 | Human Immunodeficiency Virus Type 2 [HIV-2] |
| Anticonvulsants | Clobazam | Onfi | 34510 | Generalized convulsive epilepsy without intractable epilepsy |
| | | | 34511 | Generalized convulsive epilepsy with intractable epilepsy |

Ostahand 0042

| There and a Class | Osnaria Nama | Drand Nama | Diamagia Damaga | October 1, 201 Description |
|------------------------|--|------------------|-------------------|---|
| Therapeutic Class | Generic Name | Brand Name | Diagnosis Ranges | |
| <u>Antiemetics</u> | Ondansetron solution Zofran For members 0-3 years old | | V441 Or | Gastrostomy |
| | | | 78701 Both | Nausea and Vomiting |
| | | | V5811 | Encounter for antineoplastic chemotherapy |
| | Ondansetron solution | Zofran | V441 | Gastrostomy |
| | For members 4 years of | old and up | | |
| Antifungals, Oral | Itraconazole | Onmel | 1101 | Dermatophytosis of nail (Onychomycosis) |
| | | - | | (Non-Covered Service for code not listed) |
| | Itraconazole | Sporanox | 1120 | Candidiasis of mouth (Thrush) |
| | | | 11284 | Candidial esophagitis |
| | | | 1150> 1159 | Histoplasmosis infection |
| | | | 1160> 1162 | Blastomycotic infection |
| | | | 1172 | Chromoblastomycosis |
| | | | 1173 | Aspergilloisis |
| | Terbinafine | Lamisil Granules | 1100 | Dermatophytosis of scalp and beard |
| Antiparkinson's Agents | Pramipexole | Mirapex ER | 3320 | Paralysis Agitans-Parkinsonism or Parkinson's disease |
| | Ropinirole | Requip XL | 3321 | Secondary Parkinsonism |
| Anti-Ulcer Agents | Misoprostol | Cytotec | E9356 | NSAID induced gastric/duodenal ulcer |
| (Non-Covered Service | | | 53100> 53101 | Acute gastric ulcer with hemorrhage with/without obstruction |
| for code not listed) | | | 53110> 53111 | Acute gastric ulcer with perforation with/without obstruction |
| | | | 53120> 53121 | Acute gastric ulcer with hemorrhage and perforation with/without obstruction |
| | | | 53130> 53131 | Acute gastric ulcer without hemorrhage or perforation with/withou obstruction |
| | | | 53140> 53141 | Chronic or unspecified gastric ulcer with hemorrhage with/without obstruction |
| | | | 53150> 53151 | Chronic or unspecified gastric ulcer with perforation with/without obstruction |
| | | | 53160> 53161 | Chronic or unspecified gastric ulcer with hemorrhage and perforation with/without obstruction |
| | | | 53170> 53171 | Chronic gastric ulcer without hemorrhage or perforation with/without obstruction |
| | | | 53190> 53191 | Gastric ulcer unspecified as acute or chronic without hemorrhage or perforation with/without obstruction |
| | | | 53200> 53201 | Acute duodenal ulcer with hemorrhage with/without obstruction |
| | | | 53210> 53211 | Acute duodenal ulcer with perforation with/without obstruction |
| | | | 53220> 53221 | Acute duodenal ulcer with hemorrhage and perforation with/without obstruction |
| | | | 53230> 53231 | Acute duodenal ulcer without hemorrhage or perforation with/without obstruction |
| | | | 53240> 53241 | Chronic or unspecified duodenal ulcer with hemorrhage with/without obstruction |
| | | | 53250> 53251 | Chronic or unspecified duodenal ulcer with perforation with/withou obstruction |
| | | | 53260> 53261 | Chronic or unspecified duodenal ulcer with hemorrhage and perforation with/withou obstruction |
| | | | 53270> 53271 | Chronic duodenal ulcer without hemorrhage or perforation with/without obstruction |
| | | | 53290> 53291 | Duodenal ulcer unspecified as acute or chronic without hemorrhage or perofration with/without obstruction |

| | | | | October 1, 2013 |
|--|------------------------|-------------------------|------------------|--|
| Therapeutic Class | Generic Name | Brand Name | Diagnosis Ranges | Description |
| Antiviral Agents | Cidofovir | Vistide | 0785 | Cytomegaloviral disease |
| <u>Central Nervous System</u> Agents, Miscellaneous | Riluzole | Rilutek | 33520 | Amyotrophic lateral sclerosis (ALS) |
| | Tetrabenazine | Xenazine | | Requires diagnosis to be submitted on claim. |
| | Dextromethrophan/qu | uinidir Nuedexta | 340 | Multiple sclerosis |
| | | | 33520 | Amyotrophic lateral sclerosis (ALS) |
| COPD Agents | Roflumilast | Daliresp | 4910 | Simple chronic bronchitis |
| | | | 4911 | Mucopurulent chronic bronchitis |
| | | | 49120 | Obstructive chronic bronchitis without exacerbation |
| | | | 49121 | Obstructive chronic bronchitis with (acute) exacerbation |
| | | | 49122 | Obstructive chronic bronchitis with acute bronchitis |
| | | | 4918 | Other chronic bronchitis |
| | | | 4919 | Unspecified chronic bronchitis |
| | | | 496 | Chronic airway obstruction not elsewhere classified |
| Diabetic Supplies | Blood glucose calibra | tor solutions and chips | 25000> 25003 | Diabetes mellitus without mention of complication |
| (PA is not required for | Blood glucose meters | 6 | 64800 | Diabetes in pregancy unspecified |
| these diagnosis codes) | Blood glucose test str | rips | 64803 | Antepartum diabetes mellitus |
| | Insulin syringes | | 64804 | Postpartum diabetes Mellitus |
| | Lancets | | 64880 | Abnormal glucose tolerance in pregnancy unspecified |
| | Lancet devices | | 64883 | Abnormal glucose tolerance of mother antepartum |
| | | | | |
| (PA is required for these | | | 24900 | Secondary diabetes mellitus without complications [not stated] |
| diagnosis codes) | Blood glucose meters | 3 | 24901 | Secondary diabetes without complications [uncontrolled] |
| | Blood glucose test str | rips | 2508 | Diabetic Hypoglycemia |
| | Lancets | | 2511 | Hyperinsulinemic hypoglycemia |
| | Lancet devices | | 2777 | Dysmetabolic syndrome X |
| | | | 79021 | Impaired fasting glucose |
| | | | 79022 | Abnormal glucose tolerance test |
| | | | 79029 | Pre-diabetes NOS |
| Endocrine | Miglustat | Zavesca | 2727 | Gaucher's Disease |
| Agents/Enzymes | Idursulfase | Elaprase | 2775 | Mucopolysaccharidosis |
| Gamma Aminobutyric | Gabapentin | Horizant (only) | 33394 | Restless Legs Syndrom (RLS) |
| Acid Class | | | | |
| | | | 05319 | Herpes Zoster with Other Nervous System Complications |
| | Gabapentin | Gralise (only) | 05319 | Herpes Zoster with Other Nervous System Complications |
| (Non-Covered Service | | | | |
| for codes not listed) | | | | |
| Hypoglycemics, GLP 1 | Exenatide | Bydureon | 25000 | Diabetes uncomplicated Type II |
| (Requires PA) | | Byetta | 25002 | Diabetes uncomplicated Type II uncontrolled |
| (Non-Covered Service | | | | |
| for codes not listed) | Liraglutide | Victoza | | |

| | | | | October 1 | , 2013 |
|---|----------------------------------|------------------|------------------|--|--------|
| Therapeutic Class | Generic Name | Brand Name | Diagnosis Ranges | Description | |
| Hypoglycemic Symlin | Pramlintide | Symlin | 25000 | Diabetes uncomplicated Type II | |
| (Requires PA regardless | 5 | | 25001 | Diabetes Uncomplicated Type I | |
| of Dx) | | | 25002 | Diabetes uncomplicated Type II uncontrolled | |
| | | | 25003 | Diabetes uncomplicated Type I uncontrolled | |
| Immunologic Agents, Immunosuppressives | Muromonab CD3 | Orthoclone OKT-3 | 9968 | Organ transplant rejection | |
| Immunologic Agents, Interferons | Interferon Alfa 2A | Roferon-A | 07054 | Chronic hepatitis C w/o hepatic coma | |
| | | | 1729 | Malignant melanoma | |
| | | | 1760> 1769 | Kaposi's sarcoma | |
| | | | 2024 | Hairy cell leukemia | |
| | | | 2028 | Non-Hodgkin's lymphoma | |
| | | | 2030 | Multiple myeloma | |
| | | | 2051 | Chronic myelocytic leukemia | |
| | | | 2337 | Bladder carcinoma | |
| | | | 2339 | Renal cell carcinoma | |
| | Interferon Alfa 2B | Intron A | 07054 | Chronic hepatitis C w/o hepatic coma | |
| | | | 07811 | Condylomata acuminatum | |
| | | | 1729 | Malignant Melanoma | |
| | | | 1760> 1769 | Kaposi's sarcoma | |
| | | | 2024 | Hairy cell leukemia | |
| | | | 2024 | Non-Hodgkin's lymphoma | |
| | | | 2028 | Multiple myeloma | |
| | | | | | |
| | | | 2337 | Bladder carcinoma | |
| | | | 2339 | Renal cell carcinoma | |
| | Interferon Alfa N3 | Alferon N | 07811 | Condylomata acuminatum | |
| | Interferon Gamma 1B | Actimmune | 2881 | Chronic granulomatous disease | |
| | | | 75652 | Osteopetrosis | |
| Lipdystrophy | Tesamorelin | Egrifta | | | |
| (Non-Covered Service | Two diagnosis codes a | - | 042 | HIV Disease | |
| for diagnosis code not | on claim-Member mus | | 2726 | Lipodystrophy | |
| listed) | diagnosis of HIV Disease or | | or | | |
| | HIV-2 Disease plus Lipodystrophy | | 07953 2726 | Human Immunodeficiency Virus Type 2 [HIV-2] Lipodystrophy | |
| Multiple Sclerosis | Dalfampridine | Ampyra | 340 | Multiple sclerosis | |
| Agents, Other | Clinical PA required. Submit | | - | | |
| | the PA/RF and PA/DGA with | | | | |
| | supporting clinical | | | | |
| | documentation. | | | | |
| | | | | | |
| | 1 | | | 1 | |

| | | | | | October 1, 2013 |
|--|----------------------------|--------------------|------------------|---|-----------------|
| Therapeutic Class | Generic Name | Brand Name | Diagnosis Ranges | Description | |
| Oncology Agents, Oral | Cabozantinib | Cometriq | 193 | Malignant Neoplasm of thyroid | |
| | Pomalidomide | Pomalyst | 20300 | Multiple Myeloma without mention of having achievd remission | |
| | | | 20302 | Multiple Myeloma in relapse | |
| Progestin Agent | | Crinone | 6260 | Absence of menstruation (amenorrhea) | |
| | Progesterone, micronized | | | | |
| (Requires PA) (Non- Covered Service | gel | | | | |
| for code not listed) | | | | | |
| Pulmonary Anti- | Ambrisentan | Letairis | 4160 | Primary pulmonary hypertension | |
| Hypertensive Agents | | | | | |
| | Bosentan | Tracleer | 4168 | Chronic pulmonary heart disease other | |
| | lloprost | Ventavis | | | |
| | Sildenafil | Revatio | | | |
| | Tadalafil | Adcirca | | | |
| | Treprostinil | Tyvaso | | | |
| Respiratory | Alpha-1-Proteinase Inhibit | Aralast | 2734 | AAT, Alpha-1-antitrypsin deficiency | |
| Enzymes | | Glassia | | | |
| | | Prolast | | | |
| | | Zemaire | | | |
| Smoking Cessation | Bupropion | Zyban | 3051 | Tobacco use disorder | |
| | Nicotine | Nicoderm | 30510 | Tobacco abuse-Unspecified | |
| | | Nicorette | 30511 | Tobacco abuse-Continuous | |
| | | Nicotrol | 30512 | Tobacco abuse-Episodic | |
| | Varenicline Tartrate | Chantix | | | |
| Stimulants and Related | Amphetamine Salts | Adderall | 31400 - 3149 | Hyperkinetic syndrome/Attention deficit disorder of childhood | |
| Agents | | Adderall XR | 34700 | Narcolepsy without cataplexy | |
| | Dexmethylphenidate | Focalin | 34701 | Narcolepsy with cataplexy | |
| | | Focalin XR | 34710 | Narcolepsy in conditions classified elsewhere without cataplexy | |
| | Dextroamphetamine | Dexedrine Spansule | 34711 | Narcolepsy in conditions classified elsewhere with cataplexy | |
| | | Dextroamphetamine | | | |
| | | Procentra | | | |
| | Lisdexamfetamine | Vyvanse | | | |
| | Methamphetamine | Desoxyn | | | |
| | Methylphenidate | Concerta ER | | | |
| | | Daytrana | | | |
| | | Metadate CD | | | |
| | | Metadate ER | | | |
| | | Methylin | | | |
| | | Methylin ER | | | |
| | | Ritalin | | | |
| | | Ritalin LA | | | |
| Stimulants and Related | | Ritalin SR | | | |
| Agents (cont) | Atomoxetine | Strattera | 31400 - 3149 | Hyperkinetic syndrome/Attention deficit disorder of childhood | |

| | | | | | October 1, 2013 |
|--|--|---|--|---|-----------------|
| Therapeutic Class | Generic Name | Brand Name | Diagnosis Ranges | Description | |
| Therapeutic Class | Generic Name Clonidine Guanefacine | Brand Name Kapvay Intuniv ER | 29900 - 29901 29910 - 29911 29980 - 29981 29990 - 29991 31200 - 31203 31210 - 31213 31220 - 21223 31230 - 31239 3124 - 3129 31381 - 3129 | Description Autistic disorder Childhood disintegrative disorder Other specified pervasive developmental disorders Unspecified pervasive developmental disorders Undersocialized conduct disorder aggressive type Undersocialized conduct disorder unaggressive type Socialized conduct disorder Disoders of impulse control not elsewhere classified Mixed disturbance of conduct and emotions Other specified disturbances of conduct not elsewhere classified Oppositional defiant disorder | October 1, 2013 |
| | Sodium oxybate* *Clinical PA required. Submit the PA/RF and PA/DGA with supporting clinical documentation. | Xyrem* e | <u>31400 - 3149</u> 34700 34701 | Hyperkinetic syndrome/Attention deficit disorder of childhood Narcolepsy without Cataplexy Narcolepsy with cataplexy | |
| Topical, Anti-Infectives | Retapamulin | Altabax | 684 | Impetigo | |
| Topical Immunomodulators (Requires PA regardless of Dx) | Pimecrolimus Tacrolimus | Elidel Protopic | 6910 6918 | Diaper or napkin rash Other, atopic dermatitis and related conditions | |
| <u>Vitamins</u> (Non-Covered Service for codes not listed) | Prenatal Renal Care | Dialyvite Diatx Diatx FE Folbee | V22 > V222 V23 > V239 V241 > 585 585 > 5859 588 > 588 5889 > 5889 | Normal pregnancy High risk pregnancy Lactating Anemia in end-stage renal disease Chronic Kidney Disease Disorders resulting from impaired renal function Unspecified disorder resulting from impaired renal function | |
| | | Nephro-Vite Nephro-Vite +FE Renax Renax 5.5 Renax 5.6 Renax 5.7 Renax 5.8 | | | |